First‐in‐human study to assess the safety pharmacokinetics and pharmacodynamics of BMS‐962212 a direct reversible small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

摘要

AimsThe aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS‐962212, a first‐in‐class factor XIa inhibitor, in Japanese and non‐Japanese healthy subjects.